"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03254875","Rehabilitation After Breast Cancer","REBECCA II","Active, not recruiting","No Results Available","Breast Cancer","Behavioral: Individually tailored nurse navigation","Distress|Depression|Anxiety|Health related quality of life summary index|Breast cancer related quality of life summary index|Functional related quality of life summary index|Physical health related quality of life|Social health related quality of life|Emotional health related quality of life|Self-efficacy|Fear of recurrence|Pain in the breast surgery area (side of chest, armpit or arm)|Neuropathy in the breast surgery area (side of chest, armpit or arm)|Sleep quality|Cognitive function - Perceived cognitive impairments|Cognitive function- Perceived cognitive impairments|Cognitive function - Impact of Perceived cognitive impairments on quality of life|Cognitive function - Perceived cognitive abilities|Need for support|Health care costs|Acceptability","Danish Cancer Society|Rigshospitalet, Denmark|Copenhagen University Hospital at Herlev","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","324","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","REBECCA II","August 15, 2017","May 31, 2021","May 31, 2021","August 21, 2017",,"May 6, 2020","Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03254875"
2,"NCT03721211","Imaging With [11C]Martinostat in Breast Cancer",,"Withdrawn","No Results Available","Breast Cancer","Drug: [11C]Martinostat|Device: MR-PET scanner","PET-MRI Visualization and Quantification of Breast Tumor Uptake of [11C]Martinostat Above Background Uptake, as Assessed by SUV Measurements|Quantitative [11C]Martinostat-PET Uptake in Primary Breast Cancer, and Correlation with Expression of HDAC Isoforms|Correlation of Total Volume of Distribution of Dynamic [11C]Martinostat Uptake with Expression of HDAC Isoforms|Comparison of HDAC Isoform Expression by Western Blot Across Breast Tumor Subtypes|HDAC Expression Levels in Breast Tumors Compared to HDAC Expression in Adjacent Normal Breast Parenchyma","Christine Elizabeth Edmonds|Massachusetts General Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17-447","February 1, 2020","February 28, 2020","October 31, 2024","October 26, 2018",,"March 3, 2020","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03721211"
